DEA Rejects Witnesses For November Hearings On Two Psychedelic Compounds, Advocates Push Back
The Drug Enforcement Administration (DEA) has denied testimony from key witnesses ahead of scheduled hearings to discuss the potential classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC), as Schedule I substances. According to Green Market Report, this rejection has sparked a backlash from advocates, notably Students for Sensible Drug Policy (SSDP), who argue the DEA is silencing critical scientific voices.
DEA Blocks Testimonies And Exhibits
In a Motion in Limine filed on September 26, the DEA moved to exclude witnesses and exhibits proposed by SSDP, Panacea Plant Sciences and Dr. Raul A. Ramos, citing that the evidence provided was “incompetent, irrelevant, immaterial, and/or unduly repetitious.” The motion also criticized the format of the exhibits, saying they were improperly paginated and lacked identification marks, further complicating their submission for the hearings scheduled for November 12-22, with a final meeting on November 25.
The DEA argued that some witnesses presented by SSDP lacked relevant expertise, particularly targeting Panacea’s CEO, David Heldreth. According to the DEA, Heldreth is “not …